[The effect of indomethacin and carprofen on gastric prostaglandin biosynthesis].
The effect of indometacin (3 X 50 mg daily), carprofen (Imadyl) (2 X 150 mg daily) and placebo (3 X daily) on gastric juice secretion, acidity, prostanoid concentration (PGE2, PGF2 alpha and TXB2) and excretion of the major urinary metabolite of PGF (PGF-MUM) were investigated in a single-blind cross-over study in nine healthy volunteers after 3-day treatment periods separated by one-week washout periods between treatments. Indometacin proved to be a classical cyclooxygenase inhibitor (strong inhibition of PGE2 and TXB2 before and after pentagastrin stimulation and of PGF-MUM) while carprofen was an atypical inhibitor (weak inhibition of PGE2 before pentagastrin stimulation and no inhibition after, strong inhibition of TXB2 but without influence on PGF-MUM). The weak inhibition of PGE2-biosynthesis by carprofen might be related to its low incidence of gastric side effects.
D000328:Adult; D002227:Carbazoles / Q000494:pharmacology*; D015237:Dinoprost; D015232:Dinoprostone; D005753:Gastric Mucosa / Q000378:metabolism*; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D011453:Prostaglandins / Q000096:biosynthesis*; D011458:Prostaglandins E / Q000096:biosynthesis; D011460:Prostaglandins F / Q000096:biosynthesis; D011466:Prostanoic Acids / Q000096:biosynthesis; D013929:Thromboxane B2 / Q000096:biosynthesis; D013997:Time Factors
D002227:Carbazoles; D011453:Prostaglandins; D011458:Prostaglandins E; D011460:Prostaglandins F; D011466:Prostanoic Acids; C019171:prostaglandin F-main urinary metabolite; D013929:Thromboxane B2; D015237:Dinoprost; C007005:carprofen; D015232:Dinoprostone; D007213:Indomethacin
Wirkung von Indometacin und Carprofen auf die gastrale Prostaglandin-Biosynthese.